Jeff Ross, AKA the “Roastmaster General,” knows exactly what his role is. “All I gotta do is get stoned and write the jokes,” Ross told The Post in a wide-ranging interview ahead of Super ...

Leerink Partnrs also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.19) EPS. Get Aclaris Therapeutics alerts: ...

Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.04 EPS, Q4 2025 earnings at $2.84 EPS, FY2025 earnings at $11.86 EPS, FY2026 ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” the firm sees the continuation of core growth ...

This is big because a scoring winger who understands the value of playing the right way is exactly what the Oilers need right now “Jeff’s been playing really well,” said head coach Kris ...

While Jeff Lurie didn’t specifically address Nick Sirianni’s contract situation, he acknowledged that the Eagles head coach ...

The suspension was “prudent and somewhat overdue,” Leerink Partners analyst Michael Cherny said Thursday ... Gabelli Funds ...